Remicade

Background

REMICADE® was the first anti-TNF-alpha treatment to be approved in three different therapeutic areas: gastroenterology, rheumatology and dermatology. REMICADE® has demonstrated broad clinical utility with indications in Crohn's disease (CD), rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), ulcerative colitis (UC), pediatric Crohn's disease (PCD) and psoriasis (PsO). The safety and efficacy of REMICADE® have been well established in clinical trials over the past seventeen years and through commercial experience with more than one million patients treated worldwide.

REMICADE® is unique among available anti-TNF biologic therapies. It is the only anti-TNF biologic administered directly by caregivers in the clinic or office setting. REMICADE® is a two-hour infusion administered every 4 or 8 weeks (indication-dependent), following a standard induction regimen that requires treatment at weeks 0, 2 and 6. As a result, REMICADE® patients may require as few as six treatments each year as maintenance therapy.

Therapeutic Area

Rheumatoid Arthritis
Psoriatic Arthritis
Ankylosing Spondylitis
Crohn's Disease
Ulcerative Colitis

Acquisition Date

May 2007

Marketer

Marketer

Marketer

Seller